Short answer · Medically reviewed summary · Last updated: 2026-04-07
Waldenström macroglobulinemia is a rare, slow-growing type of blood cancer characterized by the uncontrolled production of a specific abnormal protein called immunoglobulin M (IgM) by cancerous white blood cells in the bone marrow. Understanding the Condition In Waldenström macroglobulinemia, the bone marrow becomes crowded with abnormal lymphoplasmacytic cells. These cells produce excessive amounts of IgM antibodies, which thicken the blood—a process known as hyperviscosity.
What is Waldenstrom Macroglobulinemia
What is Waldenstrom Macroglobulinemia? Plain-language, medically reviewed definition plus the lived reality told by patients.
Waldenström macroglobulinemia is a rare, slow-growing type of blood cancer characterized by the uncontrolled production of a specific abnormal protein called immunoglobulin M (IgM) by cancerous white blood cells in the bone marrow.
Understanding the Condition
In Waldenström macroglobulinemia, the bone marrow becomes crowded with abnormal lymphoplasmacytic cells. These cells produce excessive amounts of IgM antibodies, which thicken the blood—a process known as hyperviscosity. This thickening can impair circulation, leading to symptoms such as fatigue, blurred vision, headaches, and bleeding issues. Because it affects the bone marrow, the immune system, and the blood, Waldenström macroglobulinemia is classified as a lymphoproliferative disorder.
Who is Affected?
Waldenström macroglobulinemia is rare, with an incidence of approximately 3 to 5 cases per million people each year. It primarily affects older adults, with the median age of diagnosis typically between 65 and 70 years. While it can occur in younger individuals, it is significantly more common in men than in women and is observed more frequently in individuals of Caucasian descent.
Pathophysiology and Differentiation
The underlying mechanism of Waldenström macroglobulinemia is often driven by a specific genetic mutation known as MYD88 L265P, which is found in over 90% of patients. This mutation acts as a "switch" that keeps the cancer cells growing. Unlike multiple myeloma, which typically produces IgG or IgA proteins and causes bone lesions, Waldenström macroglobulinemia is distinguished by the massive production of IgM and the absence of the "lytic" bone lesions commonly seen in other plasma cell disorders.
Clinical Management
Because the disease often progresses slowly, some patients may remain asymptomatic for years, a state known as "smoldering" or indolent disease. Treatment is only initiated when the protein levels or cell counts begin to cause symptoms such as anemia, organ enlargement, or hyperviscosity. Modern therapeutic approaches focus on targeted therapies that inhibit the pathways used by these malignant cells to survive.
Disclaimer: This information is for educational purposes and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- Waldenström's Macroglobulinemia Foundation (IWMF)
- OMIM (Online Mendelian Inheritance in Man)
